IRLAB Therapeutics AB (publ) (STO:IRLAB.A)

IRLAB Therapeutics AB Revenue

IRLAB Therapeutics AB had revenue of 40.51M SEK in the quarter ending March 31, 2026, with 402.73% growth. This brings the company's revenue in the last twelve months to 95.24M, down -22.02% year-over-year. In the year 2025, IRLAB Therapeutics AB had annual revenue of 62.80M, down -44.95%.

• Revenue (ttm): 95.24M
• Revenue Growth: -22.02%
• P/S Ratio: 2.05
• Revenue / Employee: 2.98M
• Employees: 31
• Market Cap: 189.46M

Revenue Chart

Chart

Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	62.80M	-51.29M	-44.95%
Dec 31, 2024	114.08M	108.36M	1,894.46%
Dec 31, 2023	5.72M	-55.56M	-90.67%
Dec 31, 2022	61.28M	-146.63M	-70.53%
Dec 31, 2021	207.91M	207.50M	51,361.88%
Dec 31, 2020	404.00K	-44.00K	-9.82%
Dec 31, 2019	448.00K	252.00K	128.57%
Dec 31, 2018	196.00K	-1.02M	-83.88%
Dec 31, 2017	1.22M	-1.93M	-61.35%
Dec 31, 2016	3.15M	48.00K	1.55%
Dec 31, 2015	3.10M	-1.15M	-26.99%
Dec 31, 2014	4.24M	-	-

Data Source: Fiscal.ai Last updated: May 7, 2026

Revenue data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 22, 2026

Data Sources Report a data error